Egyptian healthtech Vezeeta will manage and operate a full medical building inside a new Cairo mixed-use development, a leap into physical healthcare delivery that comes as the company’s valuation continues to shrink in the portfolios of its venture backers.
Upwyde Developments, the real estate arm of the Upwyde group, said on Wednesday it had signed a strategic agreement with Vezeeta to run an integrated medical facility within “Prk Vie”, a large residential, office and retail project in New Cairo’s Golden Square. Vezeeta will oversee the day-to-day running of clinics and services, combining in-person care with its existing digital tools for appointment booking and practice management.
The deal is the most tangible sign yet that Egypt’s best known digital health platform is pivoting towards a hybrid model at a time when the purely online playbook is struggling to convince investors. Financial data from VNV Global, a Stockholm-listed investment firm that holds a 9% stake in Vezeeta, shows the company’s implied valuation has fallen to roughly $22.4 million as of March 2026, down from an estimated $105 million at the time of VNV’s original investment.
A digital platform with a new physical layer
Under the agreement, Vezeeta will act as the operating partner for the Prk Vie medical building rather than a tenant or owner, suggesting a capital-light approach. The facility will house a range of outpatient clinics and support services, all bookable through Vezeeta’s platform, with the company managing the patient journey from online scheduling to on-site care.
“This partnership aligns with our approach of embedding essential services within our developments,” said Fadel Samir, co-CEO of the commercial sector at Upwyde Developments, adding that healthcare offerings enhance the functionality and appeal of a mixed-use destination. “This agreement reflects broader momentum in Egypt’s healthcare sector and supports improved access to services through the integration of digital and on-the-ground operations.”
The language is bullish, but Vezeeta’s move into physical operations is unfolding against a starkly different financial backdrop.
Valuation tumbles erode a brief recovery
VNV Global first invested in Vezeeta in 2018 or earlier, ultimately deploying $9.4 million for its 9% equity stake. By the start of 2025, that stake had been marked down to just $1.59 million, implying a company valuation of about $17.7 million — a decline of more than 80% from the implied entry valuation of roughly $105 million.
A modest rally followed during 2025, when VNV’s holding bounced 66% to $2.64 million by year-end, based on a revenue multiple of 4.5x that was pegged to a now-dated transaction from September 2022. That recovery has already unravelled. In the first quarter of 2026, VNV slashed the value of its Vezeeta holding by a further $629,000, or 23.8%, to $2.014 million. The multiple used to calculate fair value was cut from 4.5x to 3.2x, reflecting a broad contraction in the trading multiples of comparable listed digital health companies.
VNV’s own commentary on its portfolio acknowledged the pressure, noting that “listed peer multiples for B2B SaaS have traded down sharply” and that its write-downs “reflect sentiment in public markets, not what’s actually being built.” Even so, the numeric arc is unforgiving: $9.4 million in, $2 million out, and a holding that remains 78.6% below cost after accounting for the brief 2025 uptick.
A separate analysis of VNV’s portfolio last year described the Vezeeta stake as “a recovering asset from a very low base, not a top performer in absolute terms” and warned that “at current trajectory, it would take several more years of similar growth just to break even.” With the latest markdown and a lower multiple, that break-even horizon has stretched further.
Why the physical pivot now
Vezeeta’s core product — a platform that lets patients search for doctors, book appointments and access teleconsultations — has been challenged by high patient no-show rates and intense competition in Egypt’s fragmented healthcare market. The company diversified into e-pharmacy and fintech (“Vezeeta Lab”) in previous years, and undertook a 10% staff reduction in 2022 to contain costs.
Operating a physical medical building inside a developer’s project represents a deeper structural shift. Instead of simply connecting patients with third-party clinics, Vezeeta now plans to manage the clinical environment itself, potentially capturing a share of facility fees, operational services and aggregated data. The model mirrors moves seen in other emerging markets, where digital health companies have opened or operated their own clinics to build trust and create a more predictable revenue stream.
Yet the move also introduces new risks. Managing a multi-clinic facility demands capabilities in licensing, equipment, staffing and regulatory compliance that go well beyond running a booking app. Egypt’s healthcare regulations have historically been cautious. Vezeeta and similar platforms previously faced legal challenges, including criminal complaints tied to rules prohibiting the online sale of medicines. The Egyptian Drug Authority has since begun rolling out a national track-and-trace system for pharmaceuticals, and the government published a National Digital Health Strategy for 2025–2029, suggesting a more accommodating climate. Still, the transition from digital intermediary to physical operator will test how far that regulatory goodwill extends.
Funding winter meets infrastructure play
Vezeeta’s pivot also comes at a time when raising growth capital for cash-burning healthtechs has become extremely difficult. The company has not announced a major equity round in several years. Breadfast, an Egyptian grocery startup also in VNV’s portfolio, closed a $50 million pre-Series C in February 2026, demonstrating that money is available for businesses with strong unit economics and vertical integration. By comparison, Vezeeta has had to settle for the more modest path of an operating partnership.
The Upwyde deal may reflect a pragmatic choice: access a physical footprint without heavy upfront capex. The developer constructs and owns the building; Vezeeta provides the operational layer. If the model works, it could be replicated across other mixed-use projects in Cairo and beyond, creating a network of Vezeeta-managed clinics that complement the digital marketplace. However, the financials will need to show meaningful new revenue quickly to shift the narrative around the company’s valuation — and to change the tone of markdowns that have become a recurring feature of its investors’ quarterly reports.
In the statement announcing the Upwyde agreement, Vezeeta’s chief corporate development officer, Choucri Asmar, said the deal “reflects broader momentum in Egypt’s healthcare sector and supports improved access to services through the integration of digital and on-the-ground operations.” That sentiment captures the ambition. VNV Global’s latest NAV statement, with the Vezeeta line falling again, captures the financial reality.
For Vezeeta, the Prk Vie medical building will be watched as a test of whether running physical clinics can finally generate the kind of value that its app alone could not.